ArticlePloS one2020

Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.

Guilherme Silva Julian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.